Evaluating deucravacitinib for moderate-to-severe plaque psoriasis in Germany
Deucravacitinib in Routine Clinical Practice: A 5-year, Multicenter, Prospective, Non-Interventional Cohort Study to Evaluate Effectiveness and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)
This study is testing how well deucravacitinib works for adults with moderate-to-severe plaque psoriasis and how it affects their quality of life over five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 550 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Drugs / interventions | deucravacitinib |
| Locations | 2 sites (Selters, Rhineland-Palatinate and 1 other locations) |
| Trial ID | NCT06104644 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of deucravacitinib treatment and its impact on the quality of life for adults suffering from moderate-to-severe plaque psoriasis in routine clinical practice over a five-year period. Participants will be adults who have been diagnosed with the condition and are starting treatment with deucravacitinib as per the approved guidelines in the European Union. The study will gather data on patient outcomes and experiences without altering their treatment plans.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a physician-confirmed diagnosis of moderate-to-severe plaque psoriasis who are initiating treatment with deucravacitinib.
Not a fit: Patients who have contraindications to deucravacitinib or have previously been treated with this medication will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of deucravacitinib, potentially improving treatment strategies for plaque psoriasis.
How similar studies have performed: While this study focuses on observational data, similar studies evaluating the effectiveness of treatments for plaque psoriasis have shown promising results, indicating that real-world evidence can complement clinical trial findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union * The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study * Patient is at least 18 years of age at the time of treatment decision * Patient provided written informed consent to participate in the study Exclusion Criteria: * Any contraindications according to the approved deucravacitinib Summary of Product Characteristics * Prior treatment with deucravacitinib * Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis
Where this trial is running
Selters, Rhineland-Palatinate and 1 other locations
- Dermatologische Spezial- und Schwerpunktpraxis Selters — Selters, Rhineland-Palatinate, Germany (Recruiting)
- Company for Medical Study & Service Selters — Selters, Germany (Recruiting)
Study contacts
- Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.